Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 1/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.55 |
| ▸ | ACHE | P22303 | 1/20 | 0.53 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.52 |
| ▸ | HRH1 | P35367 | 1/20 | 0.52 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | HTR6 | P50406 | 6/20 | 0.49 |
| ▸ | HTR1A | P08908 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
| ▸ | DRD4 | P21917 | 1/20 | 0.49 |
| ▸ | DRD3 | P35462 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8176219 | 1.00 | MC4R (0.56) | MC4RSIGMAR1ACHEADRA1AHRH1 | |
| SCHEMBL3393340 | 1.00 | MC4R (0.56) | MC4RSIGMAR1ACHEADRA1AHRH1 | |
| SCHEMBL3395798 | 0.95 | MC4R (0.54) | MC4RSIGMAR1ACHEADRA1AHRH1 | |
| SCHEMBL3395802 | 0.95 | MC4R (0.54) | MC4RSIGMAR1ACHEADRA1AHRH1 | |
| SCHEMBL13700887 | 0.82 | CCR3 (0.57) | SIGMAR1HTR1A | |
| SCHEMBL12786272 | 0.80 | CYP1A2 (0.50) | HTR6 | |
| SCHEMBL2947772 | 0.78 | MC4R (0.58) | MC4RSIGMAR1ACHEADRA1AHRH1 | |
| SCHEMBL2947770 | 0.78 | MC4R (0.58) | MC4RSIGMAR1ACHEADRA1AHRH1 | |
| SCHEMBL3764570 | 0.77 | HTR6 (0.54) | HTR6 | |
| SCHEMBL16488227 | 0.77 | HTR6 (0.54) | HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7659395-B2 | Urea derivatives as calcium channel blockers | NEUROMED PHARMACEUTICALS LTD. (CA) | 2010-02-09 | — | — | US | disclosed |
| US-7649092-B2 | Urea derivatives as calcium channel blockers | NEUROMED PHARMACEUTICALS LTD. (CA) | 2010-01-19 | — | — | US | disclosed |
| US-20080221117-A1 | UREA DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2008-09-11 | — | — | US | disclosed |
| US-20080207633-A1 | UREA DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2008-08-28 | — | — | US | disclosed |
| US-7378420-B2 | Urea derivatives as calcium channel blockers | NEUROMED PHARMACEUTICALS LTD. (CA) | 2008-05-27 | — | — | US | disclosed |
| US-20060063775-A1 | Urea derivatives as calcium channel blockers | NEUROMED TECHNOLOGIES INC. | 2006-03-23 | — | — | US | disclosed |
| US-6156752-A | Optically active 1,4-dihydropyridine compounds as bradykinin antagonists | PFIZER INC (US) | 2000-12-05 | — | — | US | disclosed |
| EP-0899261-A1 | Optical active 1,4-dihydropyridine compounds as bradykinin antagonists | PFIZER INC. (US) | 1999-03-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207633-A1 | UREA DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ORAI1, ATP2A1, CACNA1B | MC4R 4546/4885SIGMAR1 925/4885ACHE 309/4885 |
| US-20060063775-A1 | Urea derivatives as calcium channel blockers | ORAI1, ATP2A1, CACNA1B | MC4R 4546/4885SIGMAR1 925/4885ACHE 309/4885 |
| US-20080221117-A1 | UREA DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ORAI1, ATP2A1, CACNA1B | MC4R 4546/4885SIGMAR1 925/4885ACHE 309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.